Pfizer launches Inspra for heart failure.
D004345:Drug Industry; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D018161:Receptors, Mineralocorticoid / Q000187:drug effects; D013148:Spironolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy
D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000077545:Eplerenone